

BMJ Open Examining the association between serum lactic dehydrogenase and all-cause mortality in patients with metabolic syndrome: a retrospective observational study

Li-Wei Wu,^{1,2,3,4} Tung-Wei Kao,^{1,2,3} Chien-Ming Lin,⁴ Hui-Fang Yang,^{1,2} Yu-Shan Sun,^{1,2} Fang-Yih Liaw,^{1,2,3,4} Chung-Ching Wang,^{1,2} Tao-Chun Peng,^{1,2} Wei-Liang Chen^{1,2,3,4}

To cite: Wu L-W, Kao T-W, Lin C-M, *et al.* Examining the association between serum lactic dehydrogenase and all-cause mortality in patients with metabolic syndrome: a retrospective observational study. *BMJ Open* 2016;**6**: e011186. doi:10.1136/bmjopen-2016-011186

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-011186>).

Received 18 January 2016
Revised 15 March 2016
Accepted 5 May 2016



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Wei-Liang Chen;
weiliang0508@gmail.com

ABSTRACT

Objectives: Emerging evidence indicates that elevated serum lactic dehydrogenase (LDH) levels are associated with increased cardiovascular mortality, but the mechanisms for this relationship remain uncertain. Since metabolic syndrome (MetS) is correlated with a higher risk of cardiovascular complications, we investigated the joint association between serum LDH levels and all-cause mortality in the US general population with MetS.

Design: Retrospective study.

Setting: The USA.

Participants: A retrospective observational study of 3872 adults with MetS and 7516 adults without MetS in the National Health and Nutrition Examination Survey III was performed.

Main outcome measures: Participants with and without MetS were both divided into 3 groups according to their serum LDH level. Multivariable Cox regression analyses and Kaplan-Meier survival probabilities were used to jointly relate all-cause, cardiovascular and cancer mortality risk to different serum LDH levels.

Results: For all-cause mortality in participants with MetS, multivariable adjusted HRs were 1.006 (95% CI 0.837 to 1.210; $p=0.947$) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.273 (95% CI 1.049 to 1.547; $p=0.015$) for serum LDH of 176–668 U/L compared with 65–149 U/L.

Conclusions: Results support a positive association between higher level of serum LDH and mortality from all causes in individuals with MetS.

INTRODUCTION

Lactate dehydrogenase (LDH), a cytoplasmic enzyme in most tissues and organs, catalyses the interconversion of pyruvate, which is the final product of glycolysis, to lactate with

Strengths and limitations of this study

- The study used the nationwide population-based data set.
- The study explored the impact of serum lactate dehydrogenase (LDH) levels on all-cause mortality in the US general population with metabolic syndrome.
- Serum LDH levels were collected at only one point during the follow-up period.

accompanying interconversion of NADH and NAD⁺. Abnormal extracellular appearance of LDH, which is detectable in the serum and used for detection of cell or tissue damage, was reported as an ominous outcome marker in a large number of clinical conditions,^{1–4} including severe infection and sepsis, malignancies, acute myocardial infarction, and liver diseases such as cirrhosis and metastatic carcinoma of the liver. In addition, abnormal high levels of serum LDH have also been demonstrated to correlate with cardiovascular mortality of long-term arsenic exposure.⁵

Metabolic syndrome (MetS), which is an integrated concept that asserts that a common cluster of disorders including abdominal obesity, impaired fasting glucose, elevated blood pressures (BPs) and dyslipidaemia, are predictive for type 2 diabetes and atherosclerotic diseases.⁶ In the third National Health and Nutrition Examination Survey III (NHANES III), MetS prevalence in US adults increased with age and was highly prevalent.⁷ It is generally accepted that MetS is composed of several risk factors for cardiovascular complications. Lakka *et al*⁸ have demonstrated that cardiovascular and all-cause mortality in Finnish men with MetS

was significantly increased. Similar findings were reported in a previous study of NHANES II.⁹ However, few studies have addressed the association between all-cause mortality in MetS and the level of serum LDH. This prompts us to investigate the correlation between serum LDH and all-cause mortality risk in individuals with MetS using the NHANES III data.

MATERIALS AND METHODS

Study population

We selected adults with MetS aged between 20 and 59 years in the NHANES III study, which represented a multistage stratified investigation of the US population living in households during 1988–1994.¹⁰ Demographic information was collected through a structured home interview and accompanied by a series of physical examination and blood sampling at a mobile examination centre. The NHANES III study was executed in accordance with the Declaration of Helsinki and approved by the National Center for Health Statistics (NCHS) Institutional Review Board after obtaining the written informed consent of participants before starting the study.

Definition of MetS

MetS, which included ≥ 3 of the following components, was based on the revised National Cholesterol Education Program's Adult Treatment Panel III.¹¹ MetS was diagnosed at baseline for all the adult participants. The first component of MetS was raised waist circumference, which was defined by waist circumference >102 cm in men and >88 cm in women. The second component of MetS was elevated BP, which was defined by systolic BP ≥ 130 mm Hg or diastolic BP ≥ 85 mm Hg. The third component of MetS was elevated serum fasting glucose, which was defined by serum fasting glucose ≥ 100 mg/dL (5.6 mmol/L). The fourth component of MetS was raised serum triglycerides (TGs), which was defined by serum TGs ≥ 150 mg/dL (1.7 mmol/L). The fifth component of MetS was reduced serum high-density lipoprotein cholesterol (HDL-C), which was defined by HDL-C <40 mg/dL (1.03 mmol/L) for men and <50 mg/dL (1.3 mmol/L) for women.

Definition of LDH tertiles group

Serum LDH was measured at baseline for all the adult participants. We determined the LDH tertiles of study groups with MetS and chose 65–149, 149–176 and 176–668 U/L as the cut-off value for grouping. Patients were then divided into three groups (highest, middle and lowest, below and above cut-off level, respectively).

Follow-up data on all-cause mortality

The NHANES III study also contained detailed mortality information and follow-up data from the time of study participation. The follow-up data on all-cause mortality, NHANES III Linked Mortality File, were provided by the NCHS according to the probabilistic matching between

National Death Index death certificate records and NHANES III participants. The follow-up data on all-cause mortality of the NHANES III study were from 1988 to 2006.¹²

Exclusion criteria of participants

Among these populations, eligible participants with incomplete data for the serum LDH measurement, household interview, or laboratory and clinical examinations were excluded. Moreover, in order to minimise the confounding effect, we excluded participants with liver disease (level of serum aspartate aminotransferase (AST) or alanine aminotransaminase >40 U/L) or bone disease (level of serum alkaline phosphatase >117 U) at baseline.

Data analysis

All statistical procedures and analyses were implemented using SPSS V.18 (SPSS, Inc, Chicago, Illinois, USA). The analytic data were executed by the complex samples procedure to incorporate sampling weights and prevent incorrect estimates of variance. Quantitative parameters were indicated as the values of mean and SD, while qualitative data were presented as the values of number and percentage. Demographic characteristics were compared using the independent t-test or Wilcoxon rank-sum test for continuous variables and the χ^2 test for discrete variables. Two-sided p values of <0.05 were considered to indicate significance. Binary logistic regression analysis was performed for the predictive factors of all-cause mortality. Survival analysis was performed to examine the association of serum LDH with all-cause, cardiovascular and cancer mortality. Kaplan–Meier survival curves were plotted to ascertain the relationship of serum LDH in participants with MetS and subsequent mortality. Associations between serum LDH tertiles and end points were evaluated in multivariable Cox proportional hazard models. Covariates adjustment was performed by an extended model approach: Model 1 was not adjusted for other variables; model 2 was further adjusted for age, race, sex and body mass index; model 3=model 2+serum C reactive protein (CRP), serum total bilirubin, serum creatinine, serum aspartate transaminase, serum uric acid, smoking, cardiovascular disease (CVD), cancer.

RESULTS

The study population consisted of 3872 adults with MetS and 7516 adults without MetS in the NHANES III database with serum LDH levels. The clinical characteristics of the study population by serum LDH tertiles are summarised in table 1. Participants in the MetS group with higher tertiles of serum LDH levels were inclined to have higher age, higher systolic and diastolic BP, higher waist circumference, higher serum HDL-C level, higher serum uric acid level and higher serum AST level. Participants in the MetS group with higher serum LDH

Table 1 Characteristics of study participants with and without MetS

Characteristic	MetS group			Total n=3872	p Value	Non-MetS group			Total n=7516	p Value
	Tertiles of serum LDH levels (U/L)					Tertiles of serum LDH levels (U/L)				
	65–149 (U/L) n=1279	149–176 (U/L) n=1316	176–668 (U/L) n=1277			36–138 (U/L) n=2522	138–163 (U/L) n=2487	163–454 (U/L) n=2507		
<i>Continuous variables</i>										
Serum LDH, mean (SD)	131.12 (15.10)	162.96 (7.56)	203.92 (30.69)	165.96 (35.84)	<0.001	121.41 (13.82)	150.41 (7.22)	188.65 (24.48)	153.43 (32.28)	<0.001
Age (years), mean (SD)	51.93 (17.66)	56.34 (17.83)	58.61 (17.96)	55.63 (18.03)	<0.001	38.09 (15.40)	41.85 (16.99)	46.75 (18.91)	42.22 (17.52)	<0.001
Systolic blood pressure, mean (SD)	132.12 (20.70)	136.79 (22.05)	141.59 (23.93)	136.86 (22.60)	<0.001	114.14 (15.03)	117.65 (17.20)	121.81 (20.02)	117.86 (17.81)	<0.001
Diastolic blood pressure, mean (SD)	75.21 (13.12)	76.25 (12.79)	76.69 (14.94)	76.06 (13.66)	0.022	68.49 (12.14)	70.64 (11.43)	71.09 (13.02)	70.07 (12.27)	<0.001
Waist circumference (cm), mean (SD)	101.16 (12.23)	102.77 (12.73)	102.78 (13.32)	102.24 (12.79)	0.001	85.26 (11.57)	87.22 (11.99)	89.63 (12.53)	87.37 (12.17)	<0.001
Serum triglycerides (mg/dL), mean (SD)	156.33 (114.58)	155.77 (117.28)	150.40 (110.12)	154.18 (114.07)	0.349	124.08 (105.63)	128.45 (94.37)	133.70 (90.53)	128.73 (97.14)	0.002
Serum HDL-C (mg/dL), mean (SD)	44.93 (14.73)	45.82 (13.56)	48.61 (15.03)	46.45 (14.53)	<0.001	53.46 (14.21)	53.72 (14.69)	54.99 (15.66)	54.06 (14.88)	0.001
Serum glucose, mean (SD)	112.41 (47.24)	113.16 (46.89)	108.28 (35.24)	111.30 (43.56)	0.009	89.15 (20.11)	90.59 (19.46)	92.27 (21.13)	90.67 (20.28)	<0.001
Serum CRP, mean (SD)	0.56 (0.83)	0.54 (0.74)	0.55 (0.76)	0.55 (0.77)	0.717	0.38 (0.79)	0.34 (0.41)	0.40 (0.64)	0.37 (0.63)	0.005
Serum uric acid, mean (SD)	5.43 (1.46)	5.69 (1.52)	5.69 (1.54)	5.60 (1.51)	<0.001	4.87 (1.34)	5.10 (1.35)	5.34 (1.48)	5.10 (1.41)	<0.001
AST (U/L), mean (SD)	17.95 (4.95)	19.56 (5.33)	21.13 (5.34)	19.55 (5.37)	<0.001	17.82 (4.58)	19.44 (4.91)	21.87 (5.62)	19.71 (5.32)	<0.001
Serum total bilirubin, mean (SD)	0.55 (0.28)	0.55 (0.25)	0.55 (0.26)	0.55 (0.26)	0.821	0.50 (0.35)	0.60 (0.30)	0.61 (0.33)	0.60 (0.33)	0.679
<i>Categorical variables</i>										
Male, n (%)	548 (42.8)	541 (41.1)	452 (35.4)	1541 (39.8)	<0.001	1134 (45.0)	1261 (50.7)	1257 (50.1)	3652 (48.6)	<0.001
Non-Hispanic white, n (%)	581 (45.4)	652 (49.5)	553 (43.3)	1786 (46.1)	<0.001	1122 (44.5)	1117 (44.9)	1029 (41.0)	3268 (43.5)	<0.001
Diabetes mellitus, n (%)	188 (14.7)	178 (13.5)	148 (11.6)	514 (13.3)	0.161	48 (1.9)	66 (2.7)	89 (3.6)	203 (2.7)	0.001
Malignancy, n (%)	46 (3.6)	70 (5.3)	61 (4.8)	177 (4.6)	0.158	56 (2.2)	80 (3.2)	91 (3.6)	227 (3.0)	0.011
Stroke, n (%)	36 (2.8)	56 (4.3)	65 (5.1)	157 (4.1)	0.047	20 (0.8)	31 (1.2)	50 (2.0)	101 (1.3)	0.001
Congestive heart failure, n (%)	41 (3.2)	68 (5.2)	63 (4.9)	172 (4.4)	0.101	41 (1.6)	45 (1.8)	63 (2.5)	149 (2.0)	0.051
Smoker, n (%)	176 (13.8)	190 (14.4)	134 (10.5)	500 (12.9)	0.006	246 (9.8)	270 (10.9)	240 (9.6)	756 (10.1)	0.264

AST, aspartate aminotransferases; CRP, C reactive protein; HDL-C, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase; MetS, metabolic syndrome.

levels were less likely to be ever-smokers. The univariate comparisons between patients with MetS and non-MetS with and without death are shown in table 2. The unadjusted associations of serum LDH tertiles with mortality in participants with MetS are shown in figure 1. Higher serum LDH level had lower cumulative survival in those with MetS. The predictive factors of all-cause mortality according to binary logistic regression analysis (shown in table 3) were the serum LDH (OR 1.005, 95% CI 1.003 to 1.007), age (OR 1.114, 95% CI 1.106 to 1.122), systolic BP (OR 1.036, 95% CI 1.032 to 1.039), serum TG (OR 1.002, 95% CI 1.001 to 1.002), serum HDL-C (OR 1.005, 95% CI 1.000 to 1.009), serum glucose (OR 1.008, 95% CI 1.007 to 1.010), waist circumference (OR 0.999, 95% CI 0.994 to 1.004) and serum CRP (OR 1.121, 95% CI 1.032 to 1.219).

For all-cause mortality in participants with MetS (shown in table 4), the unadjusted HRs of mode 1 for each tertiles of increasing serum LDH were 1.205 (95% CI 1.007 to 1.441; $p=0.041$) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.572 (95% CI 1.315 to 1.881; $p<0.001$) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 2 for each tertiles of increasing serum LDH were 0.980 (95% CI 0.819 to 1.174; $p=0.827$) for serum LDH of 149–176 U/L compared




Figure 1 Kaplan-Meier plot of association of serum lactate dehydrogenase tertiles with mortality in participants with metabolic syndrome.

with 65–149 U/L, and 1.220 (95% CI 1.017 to 1.463; $p=0.033$) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 3 for each tertiles of increasing serum LDH were 1.006 (95% CI 0.837 to 1.210;

Table 2 Univariate comparisons between patients with MetS and non-MetS with and without death

Characteristic	MetS group		p Value	Non-MetS group		p Value
	Alive group Total n=2574	Death group Total n=1298		Alive group Total n=6401	Death group Total n=1115	
<i>Continuous variables</i>						
Serum LDH, mean (SD)	163.93 (33.70)	169.95 (39.47)	<0.001	151.74 (31.51)	163.01 (34.86)	<0.001
Age (years), mean (SD)	48.01 (15.43)	70.75 (12.38)	<0.001	38.14 (14.09)	65.70 (16.83)	<0.001
Systolic blood pressure, mean (SD)	131.36 (20.35)	147.70 (22.88)	<0.001	115.25 (14.91)	133.01 (24.51)	<0.001
Diastolic blood pressure, mean (SD)	76.90 (13.10)	74.38 (14.55)	<0.001	69.91 (11.66)	70.96 (15.31)	0.009
Waist circumference (cm), mean (SD)	102.31 (13.07)	102.12 (12.22)	0.669	86.73 (12.14)	90.94 (11.67)	<0.001
Serum triglycerides (mg/dL), mean (SD)	146.95 (110.36)	168.66 (119.85)	<0.001	125.01 (97.35)	149.98 (93.15)	<0.001
Serum HDL-C (mg/dL), mean (SD)	46.12 (14.25)	47.11 (15.06)	0.045	54.09 (14.64)	53.86 (16.21)	0.626
Serum glucose, mean (SD)	106.01 (35.48)	121.83 (54.77)	<0.001	89.43 (16.46)	97.75 (34.08)	<0.001
Serum CRP, mean (SD)	0.52 (0.72)	0.60 (0.86)	0.006	0.35 (0.59)	0.48 (0.83)	<0.001
Serum uric acid, mean (SD)	5.45 (1.44)	5.91 (1.59)	<0.001	5.01 (1.37)	5.59 (1.53)	<0.001
AST (U/L), mean (SD)	19.48 (5.39)	19.68 (5.32)	0.286	19.62 (5.32)	20.21 (5.33)	0.001
Serum total bilirubin, mean (SD)	0.54 (0.26)	0.58 (0.27)	<0.001	0.60 (0.33)	0.59 (0.31)	0.276
<i>Categorical variables</i>						
Male, n (%)	904 (35.1)	637 (49.1)	<0.001	2935 (45.9)	714 (64.0)	<0.001
Non-Hispanic white, n (%)	985 (38.3)	800 (61.6)	<0.001	2604 (40.7)	662 (59.4)	<0.001
Diabetes mellitus, n (%)	237 (9.2)	277 (21.3)	<0.001	121 (1.9)	81 (7.3)	<0.001
Malignancy, n (%)	66 (2.6)	111 (8.6)	<0.001	124 (1.9)	103 (9.2)	<0.001
Stroke, n (%)	36 (1.4)	121 (9.3)	<0.001	35 (0.5)	66 (5.9)	<0.001
Congestive heart failure, n (%)	63 (2.4)	109 (8.4)	<0.001	55 (0.9)	94 (8.4)	<0.001
Smoker, n (%)	247 (9.6)	253 (19.5)	<0.001	532 (8.3)	224 (20.1)	<0.001

AST, aspartate aminotransferases; CRP, C reactive protein; HDL-C, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase; MetS, metabolic syndrome.

Table 3 Binary logistic regression analysis for the predictive factors of all-cause mortality in patients with metabolic syndrome

Variable	OR	95% CI	p Value
Serum LDH	1.005	1.003 to 1.007	<0.0001
Age	1.114	1.106 to 1.122	<0.0001
SBP	1.036	1.032 to 1.039	<0.0001
Serum TG	1.002	1.001 to 1.002	<0.0001
Serum HDL-C	1.005	1.000 to 1.009	0.045
Serum glucose	1.008	1.007 to 1.010	<0.0001
Waist circumference	0.999	0.994 to 1.004	0.669
Serum CRP	1.121	1.032 to 1.219	0.007

CRP, C reactive protein; HDL-C, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase; SBP, systolic blood pressure; TG, triglyceride.

p=0.947) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.273 (95% CI 1.049 to 1.547; p=0.015) for serum LDH of 176–668 U/L compared with 65–149 U/L.

For cardiovascular mortality in participants with MetS (shown in table 5), the unadjusted HRs of mode 1 for each tertiles of increasing serum LDH were 1.394 (95% CI 1.054 to 1.842; p=0.020) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.897 (95% CI 1.440 to 2.499; p<0.001) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 2 for each tertiles of increasing serum LDH were 1.061 (95% CI 0.802 to 1.405; p=0.678) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.339 (95% CI 1.010 to 1.775; p=0.042) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 3 for each tertiles of increasing serum LDH were 1.044 (95% CI 0.783 to 1.393; p=0.769) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.280 (95% CI 0.944 to 1.734; p=0.112) for serum LDH of 176–668 U/L compared with 65–149 U/L.

For cancer mortality in participants with MetS (shown in table 6), the unadjusted HRs (HRs) of mode 1 for each tertiles of increasing serum LDH were 0.844 (95% CI 0.593 to 1.200; p=0.345) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.294 (95% CI 0.939 to 1.784; p=0.115) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 2 for each tertiles of increasing serum LDH were 0.649 (95% CI 0.455 to 0.926; p=0.017) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.029 (95% CI 0.740 to 1.430; p=0.867) for serum LDH of 176–668 U/L compared with 65–149 U/L, respectively. The multivariable adjusted HRs of mode 3 for each tertiles of increasing serum LDH were 0.725 (95% CI 0.502 to 1.048; p=0.087) for serum LDH of 149–176 U/L compared with 65–149 U/L, and 1.221 (95% CI 0.852 to 1.751; p=0.277) for serum LDH of 176–668 U/L compared with 65–149 U/L.

DISCUSSION

Some prior studies have reported that serum LDH is a distinguishing clinical biomarker of severe underlying diseases, including solid and haematological malignancies, sepsis and severe infections.¹³ Moreover, several inflammatory diseases were also correlated with serum LDH. Recent research has highlighted the correlation between serum LDH levels and the long-term effect of chronic arsenic exposure on CVD.⁵ However, the link between serum LDH levels and all-cause mortality in patients with MetS has not been comprehensively evaluated. In this study, we examined the hypothesis that the relationship of serum LDH with all-cause mortality can be explained by the associations of both of these factors with MetS. Most notably, this is the first study, to the best of our knowledge, to demonstrate the relationship between serum LDH and all-cause mortality in the US population with MetS. We found that the link of serum LDH with mortality in participants with MetS persisted after various strategies for multiple covariates

Table 4 Cox proportional hazards regression of all-cause mortality for serum LDH in those with and without MetS

Models*	MetS			Non-MetS		
	Serum LDH level tertiles	HR (95% CI)	p Value	Serum LDH level tertiles	HR (95% CI)	p Value
Model 1	T2 vs T1	1.205 (1.007 to 1.441)	0.041	T2 vs T1	1.557 (1.286 to 1.886)	<0.001
	T3 vs T1	1.572 (1.315 to 1.881)	<0.001	T3 vs T1	2.133 (1.774 to 2.564)	<0.001
Model 2	T2 vs T1	0.980 (0.819 to 1.174)	0.827	T2 vs T1	1.122 (0.925 to 1.361)	0.242
	T3 vs T1	1.220 (1.017 to 1.463)	0.033	T3 vs T1	1.070 (0.884 to 1.295)	0.486
Model 3	T2 vs T1	1.006 (0.837 to 1.210)	0.947	T2 vs T1	1.191 (0.980 to 1.448)	0.079
	T3 vs T1	1.273 (1.049 to 1.547)	0.015	T3 vs T1	1.213 (0.992 to 1.484)	0.060

*Adjusted covariates.

Model 1=unadjusted.

Model 2=adjustment for age, race, sex and BMI.

Model 3=model 2+serum CRP, serum total bilirubin, serum creatinine, serum aspartate transaminase, serum uric acid, smoking, CVD, cancer. BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; LDH, lactate dehydrogenase; MetS, metabolic syndrome.

Table 5 Cox proportional hazards regression of cardiovascular mortality for serum LDH in those with and without MetS

Models*	MetS			Non-MetS		
	Serum LDH level tertiles	HR (95% CI)	p Value	Serum LDH level tertiles	HR (95% CI)	p Value
Model 1	T2 vs T1	1.394 (1.054 to 1.842)	0.020	T2 vs T1	1.687 (1.230 to 2.314)	0.001
	T3 vs T1	1.897 (1.440 to 2.499)	<0.001	T3 vs T1	2.801 (2.084 to 3.765)	<0.001
Model 2	T2 vs T1	1.061 (0.802 to 1.405)	0.678	T2 vs T1	1.256 (0.915 to 1.724)	0.159
	T3 vs T1	1.339 (1.010 to 1.775)	0.042	T3 vs T1	1.155 (0.851 to 1.566)	0.355
Model 3	T2 vs T1	1.044 (0.783 to 1.393)	0.769	T2 vs T1	1.153 (0.836 to 1.591)	0.385
	T3 vs T1	1.280 (0.944 to 1.734)	0.112	T3 vs T1	1.195 (0.865 to 1.651)	0.280

*Adjusted covariates.

Model 1=unadjusted.

Model 2=adjustment for age, race, sex and BMI.

Model 3=model 2+serum CRP, serum total bilirubin, serum creatinine, serum aspartate transaminase, serum uric acid, smoking, CVD, cancer. BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; LDH, lactate dehydrogenase; MetS, metabolic syndrome.

adjustment. These findings confirmed that the association of serum LDH level with mortality was observed in patients with MetS, with 19% higher hazard for all-cause mortality.

Systemic inflammatory indicators, including serum levels of CRP and LDH, may be a useful clinical prognostic indicator for survival and predicts the response for management in patients with specific disease. In a prior study of 213 patients with diffuse large B cell lymphoma receiving chemotherapy, high serum LDH level and systemic inflammation score were poor prognostic factors for overall survival.¹⁴ Moreover, Castelli *et al*¹⁵ found that in elderly individuals with pulmonary embolism, serum LDH level was a good predictor of short-term mortality due to the applicability and simpleness for routine use based on common clinical practice. In a recently published study conducted by Okur *et al*,¹⁶ concerning the clinical and laboratory features of those with respiratory failure and pneumonia caused by H1N1 influenza A virus, mortality was demonstrated to be significantly associated with an elevated serum LDH level. Similar inter-relations were observed from overall survival in patients with metastatic renal cell carcinoma,¹⁷ diagnosis of acute respiratory distress syndrome in the population at risk,¹⁸ early mortality in peritonitis-induced sepsis¹⁹ and mortality in

postinfarction myocardial rupture.²⁰ These findings tend to indicate that serum LDH has significant prognostic value for clinical practice and our results strongly confirm another potential prediction of mortality in patients with MetS.

A variety of factors were associated with increased risk of MetS, including obesity, a sedentary lifestyle, insulin resistance and consumption of soft drinks.²¹ MetS was a condition of chronic low-grade inflammation as a consequence of complex interplay between genetic and environmental factors.²² Inflammation might be another potential explanation for the associations of elevated serum LDH with mortality in those with MetS. Several prior studies showed a clear and strong relationship between elevated levels of CRP and increased components of MetS, which linked with a greater chance of future CVD events.²²⁻²³ Furthermore, it had been showed that CRP levels may represent as an independent predictor for poor clinical outcomes in MetS.²³ The paper in Drent *et al*²⁴ provided the latent utility of serum LDH as an inflammation biomarker in a large number of pulmonary diseases. There was a moderate positive correlation between CRP and LDH isoenzymes in those with chronic inflammatory disease, such as chronic obstructive pulmonary disease.²⁵ These observations

Table 6 Cox proportional hazards regression of cancer mortality for serum LDH in those with and without MetS

Models*	MetS			Non-MetS		
	Serum LDH level tertiles	HR (95% CI)	p Value	Serum LDH level tertiles	HR (95% CI)	p Value
Model 1	T2 vs T1	0.844 (0.593 to 1.200)	0.345	T2 vs T1	1.464 (1.032 to 2.075)	0.032
	T3 vs T1	1.294 (0.939 to 1.784)	0.115	T3 vs T1	1.860 (1.328 to 2.606)	<0.001
Model 2	T2 vs T1	0.649 (0.455 to 0.926)	0.017	T2 vs T1	1.119 (0.787 to 1.589)	0.531
	T3 vs T1	1.029 (0.740 to 1.430)	0.867	T3 vs T1	0.847 (0.595 to 1.205)	0.357
Model 3	T2 vs T1	0.725 (0.502 to 1.048)	0.087	T2 vs T1	1.169 (0.818 to 1.671)	0.392
	T3 vs T1	1.221 (0.852 to 1.751)	0.277	T3 vs T1	1.067 (0.731 to 1.556)	0.738

*Adjusted covariates.

Model 1=unadjusted.

Model 2=adjustment for age, race, sex and BMI.

Model 3=model 2+serum CRP, serum total bilirubin, serum creatinine, serum aspartate transaminase, serum uric acid, smoking, CVD, cancer. BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; LDH, lactate dehydrogenase; MetS, metabolic syndrome.

provided strong evidence that serum LDH was closely associated with inflammation. In our study, LDH may be as a systemic inflammatory marker and the association of mortality with serum LDH remained significant after statistical adjustment for CRP. Our results provide that the persistence of the serum LDH–mortality relationship after multiple covariates adjustment indicates that serum LDH can be viewed as a significant clinical biomarker that is positively associated with increased mortality in patients with MetS.

However, there were several potential limitations in this study. First, serum LDH was collected at only one point during the follow-up period, which contributed to the biased results. Second, our study was a retrospective, observational analysis of an existing database that limited causal inferences. Third, residual confounding due to unmeasured confounders of the associations of serum LDH with mortality cannot be ruled out. Finally, owing to the unavailable isoforms of LDH, we failed to draw inferences on whether the diversity of LDH was associated with increased survival or mortality.

In conclusion, the results of this study signify that in the US general population with MetS, higher serum LDH levels substantially increased the risk of all-cause mortality. Further studies should therefore determine the molecular mechanism of the causal pathways involved in the correlation of elevated serum LDH levels with mortality.

Author affiliations

¹Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC)

²School of Medicine, National Defense Medical Center, Taipei, Taiwan (ROC)

³Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC)

⁴Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan (ROC)

Contributors L-WW contributed to the design of the study and to the initial data analysis and interpretation. He was responsible for the management and retrieval of data and also drafted the initial manuscript. L-WW and W-LC were also responsible for the data analysis decisions. W-LC conceptualised and designed the study, supervised all aspects of the study, critically reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors meet the ICMJE criteria for authorship.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data are available at the NHANES website (<http://www.cdc.gov/nchs/nhanes.htm>).

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Cobben NA, Drent M, Schols AM, *et al*. Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers. *Respir Med* 1997;91:616–23.

2. Glick JH Jr. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. *Am J Clin Pathol* 1969;52:320–8.
3. Matusiewicz SP, Williamson IJ, Sime PJ, *et al*. Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis. *Eur Respir J* 1993;6:1282–6.
4. Moss DW, Henderson AR. Enzymes. In: Burtis CA, Ashwood ER, eds. *Tietz textbook of clinical chemistry*. 2nd edn. Philadelphia: W. B. Saunders, 1986:735–896.
5. Liao YT, Chen CJ, Li WF, *et al*. Elevated lactate dehydrogenase activity and increased cardiovascular mortality in the arsenic-endemic areas of southwestern Taiwan. *Toxicol Appl Pharmacol* 2012;262:232–7.
6. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. *JAMA* 2003;290:932–40.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002;287:356–9.
8. Lakka HM, Laaksonen DE, Lakka TA, *et al*. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709–16.
9. Malik S, Wong ND, Franklin SS, *et al*. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. *Circulation* 2004;110:1245–50.
10. Hyattsville, National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. *Vital Health Stat 1* 1994;32:1–407.
11. Grundy SM, Cleeman JI, Daniels SR, *et al*. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735–52.
12. Hyattsville. The Third National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File, Mortality follow-up through 2006: Matching Methodology. 2009. (accessed 21 May 2014).
13. Huijgen HJ, Sanders GT, Koster RW, *et al*. The clinical value of lactate dehydrogenase in serum: a quantitative review. *Eur J Clin Chem Clin Biochem* 1997;35:569–79.
14. Jung SH, Yang DH, Ahn JS, *et al*. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-Cell lymphoma. *Acta Haematol* 2014;133:10–17.
15. Castelli R, Bucciarelli P, Porro F, *et al*. Pulmonary embolism in elderly patients: prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. *Thromb Res* 2014;134:326–30.
16. Okur M, Erbey F, Yazicioglu O, *et al*. H1N1 influenza A virus related pneumonia and respiratory failure. *Indian J Virol* 2013;24:85–9.
17. Cetin B, Afsar B, Deger SM, *et al*. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. *Int Urol Nephrol* 2014;46:1081–7.
18. Terpstra ML, Aman J, van Nieuw Amerongen GP, *et al*. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care Med* 2014;2:691–700.
19. Liao MH, Chen SJ, Tsao CM, *et al*. Possible biomarkers of early mortality in peritonitis-induced sepsis rats. *J Surg Res* 2013;183:362–70.
20. Yuan SM, Jing H, Lavee J. The implications of serum enzymes and coagulation activities in postinfarction myocardial. *Rev Bras Cir Cardiovasc* 2011;26:7–14.
21. Dhingra R, Sullivan L, Jacques PF, *et al*. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. *Circulation* 2007;116:480–8.
22. Kaur J. A comprehensive review on metabolic syndrome. *Cardiol Res Pract* 2014;2014:943162.
23. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. *J Am Osteopath Assoc* 2005;105:409–16.
24. Drent M, Cobben NA, Henderson RF, *et al*. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *Eur Respir J* 1996;9:1736–42.
25. Nillawar AN, Bardapurkar JS, Bardapurkar SJ. High sensitive C-reactive protein as a systemic inflammatory marker and LDH-3 isoenzyme in chronic obstructive pulmonary disease. *Lung India* 2012;29:24–9.